CrossMark

ERRATUM

Erratum to: GC and VDR SNPs and Vitamin D Levels in Parkinson's Disease: The Relevance to Clinical Features

Duygu Gezen-Ak[1] · Merve Alaylıoğlu[1] · Gençer Genç[2] · Ayşegül Gündüz[3] ·
Esin Candaş[1] · Başar Bilgiç[4] · İrem L. Atasoy[1] · Hülya Apaydın[3] ·
Güneş Kızıltan[3] · Hakan Gürvit[4] · Haşmet Hanağası[4] · Sibel Ertan[3] ·
Selma Yılmazer[1] · Erdinç Dursun[1]

Erratum to: Neuromol Med
DOI 10.1007/s12017-016-8415-9

Tables 3, 4 and supplementary Table 4 of the original article contained errors in the labeling of the genotype and allele columns for the first GC SNP (rs2282679). The correct labels for the genotype columns (left to right) are 'AA', 'CA' and 'CC'. The correct labels for the allele columns (left to right) are 'A' and 'C'. The error did not affect the genotype or allele distributions, statistical analysis or results, and thus the conclusions of the study were not affected. The authors regret the inconvenience caused to the readers. The corrected Tables 3, 4 and supplementary Table 4 are given along with this erratum.

✉ Duygu Gezen-Ak
   duygugezenak@gmail.com

✉ Erdinç Dursun
   erdincdu@yahoo.com

[1] Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University, 34098 Istanbul, Turkey

[2] Department of Neurology, Gumussuyu Military Hospital, Istanbul, Turkey

[3] Department of Neurology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey

[4] Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

Table 3 Distribution of GC gene rs2282679, rs3755967, rs2298850, rs7041 and VDR gene rs731236 (TaqI), rs7975232 (ApaI), rs757343 (Tru9I), rs1544410 (BsmI), rs2228570 (FokI) genotypes and alleles

GC SNPs	Groups	Genotype			p value	Allele		p value
		AA	CA	CC		A	C	
rs2282679	All PD (n = 382)	220 (57.6 %)	140 (36.6 %)	22 (5.8 %)	0.19	580 (75.9 %)	184 (24.1 %)	0.67
	PD sporadic (n = 292)	168 (57.5 %)	106 (36.3 %)	18 (6.2 %)	0.29	442 (75.7 %)	142 (24.3 %)	0.63
	PD sporadic age of onset >50 (n = 205)	118 (57.6 %)	72 (35.1 %)	15 (7.3 %)	0.54	308 (75.1 %)	102 (24.9 %)	0.52
	PD sporadic age of onset <50 (n = 87)	50 (57.5 %)	34 (39.1 %)	3 (3.4 %)	0.16	134 (77.0 %)	40 (23.0 %)	0.99
	PD with familial background (n = 90)	52 (57.8 %)	34 (37.8 %)	4 (4.4 %)	0.29	138 (76.7 %)	42 (23.3 %)	0.93
	Healthy subjects (n = 226)	140 (61.9 %)	68 (30.1 %)	18 (8 %)		348 (77.0 %)	104 (23.0 %)	
		GG	GA	AA		G	A	
rs3755967	All PD (n = 382)	218 (57.1 %)	142 (37.2 %)	22 (5.8 %)	0.25	578 (75.7 %)	186 (24.3 %)	0.45
	PD sporadic (n = 292)	166 (56.8 %)	108 (37.0 %)	18 (6.2 %)	0.32	440 (75.3 %)	144 (24.7 %)	0.41
	PD sporadic age of onset >50 (n = 205)	117 (57.1 %)	73 (35.6 %)	15 (7.3 %)	0.53	307 (74.9 %)	103 (25.1 %)	0.36
	PD sporadic age of onset <50 (n = 87)	49 (56.3 %)	35 (40.2 %)	3 (3.4 %)	0.18	133 (76.4 %)	41 (23.6 %)	0.77
	PD with familial background (n = 90)	52 (57.8 %)	34 (37.8 %)	4 (4.4 %)	0.38	138 (76.7 %)	42 (23.3 %)	0.81
	Healthy subjects (n = 226)	140 (62.2 %)	69 (30.7 %)	16 (7.1 %)		349 (77.6 %)	101 (22.4 %)	
		CC	CG	GG		C	G	
rs2298850	All PD (n = 382)	219 (57.3 %)	141 (36.9 %)	22 (5.8 %)	0.74	579 (75.8 %)	185 (24.2 %)	0.66
	PD sporadic (n = 292)	167 (57.2 %)	107 (36.6 %)	18 (6.2 %)	0.79	441 (75.5 %)	143 (24.5 %)	0.61
	PD sporadic age of onset >50 (n = 205)	117 (57.1 %)	73 (35.6 %)	15 (7.3 %)	0.79	307 (74.9 %)	103 (25.1 %)	0.49
	PD sporadic age of onset <50 (n = 87)	50 (57.5 %)	34 (39.1 %)	3 (3.4 %)	0.48	134 (77.0 %)	40 (23.0 %)	0.97
	PD with familial background (n = 90)	52 (57.8 %)	34 (37.8 %)	4 (4.4 %)	0.70	138 (76.7 %)	42 (23.3 %)	0.95
	Healthy subjects (n = 226)	135 (60.0 %)	76 (33.8 %)	14 (6.2 %)		346 (76.9 %)	104 (23.1 %)	
		GG	GT	TT		G	T	
rs7041	All PD (n = 382)	125 (32.7 %)	175 (45.8 %)	82 (21.5 %)*	0.043* OR 1.8 95 % CI 1.1–2.8	425 (55.6 %)	339 (44.4 %)	0.09
	PD sporadic (n = 292)	100 (34.2 %)	129 (44.2 %)	63 (21.6 %)	0.040* OR 1.8 95 % CI 1.1–2.9	329 (56.3 %)	255 (43.7 %)	0.18
	PD sporadic age of onset >50 (n = 205)	70 (34.1 %)	90 (43.9 %)	45 (22.0 %)	0.049* OR 1.8 95 % CI 1.1–3.0	230 (56.1 %)	180 (43.9 %)	0.19
	PD sporadic age of onset <50 (n = 87)	30 (34.5 %)	39 (44.8 %)	18 (20.7 %)	0.24	99 (56.9 %)	75 (43.1 %)	0.41
	PD with familial background (n = 90)	25 (27.8 %)	46 (51.1 %)	19 (21.1 %)	0.19	96 (53.3 %)	84 (46.7 %)	0.10
	Healthy subjects (n = 225)	77 (34.4 %)	117 (52.2 %)	30 (13.4 %)		271 (60.5 %)	177 (39.5 %)	

VDR SNPs	Groups	Genotype			p value	Allele		p value
		TT (TT)	TC (Tt)	CC (tt)		T (T)	C (t)	
rs731236 (TaqI)	All PD (n = 381)	154 (40.4 %)	182 (47.8 %)	45 (11.8 %)	0.24	490 (64.3 %)	272 (35.7 %)	0.58
	PD sporadic (n = 292)	118 (40.4 %)	142 (48.6 %)	32 (11.0 %)	0.18	378 (64.7 %)	206 (35.3 %)	0.71
	PD sporadic age of onset >50 (n = 205)	86 (42.0 %)	98 (47.8 %)	21 (10.2 %)	0.27	270 (65.9 %)	140 (34.1 %)	0.99
	PD sporadic age of onset <50 (n = 87)	32 (36.8 %)	44 (50.6 %)	11 (12.6 %)	0.28	108 (62.1 %)	66 (37.9 %)	0.37
	PD with familial background (n = 89)	36 (40.4 %)	40 (44.9 %)	13 (14.6 %)	0.72	112 (62.9 %)	66 (37.1 %)	0.48
	Healthy subjects (n = 240)	109 (45.4 %)	98 (40.8 %)	33 (13.8 %)		316 (65.8 %)	164 (34.2 %)	

Table 3 continued

		AA (AA)	AC (Aa)	CC (aa)		A (A)	C (a)	
rs7975232 (ApaI)	All PD (n = 381)	130 (34.1 %)	194 (50.9 %)	57 (15 %)	0.077	454 (59.6 %)	308 (40.4 %)*	0.029* OR 1.3 95 % CI 1.03–1.65
	PD sporadic (n = 292)	95 (32.5 %)	152 (52.1 %)	45 (15.4 %)	0.045* OR 1.6 95 % CI 1.0–2.7	342 (58.6 %)	242 (41.4 %)	0.016* OR 1.4 95 % CI 1.1–1.7
	PD sporadic age of onset >50 (n = 205)	68 (33.2 %)	101 (49.3 %)	36 (17.6 %)	0.039* OR 1.8 95 % CI 1.1–3.2	237 (57.8 %)	173 (42.2 %)	0.015* OR 1.4 95 % CI 1.1–1.8
	PD sporadic age of onset <50 (n = 87)	27 (31.0 %)	51 (58.6 %)	9 (10.3 %)	0.18	105 (60.3 %)	69 (39.7 %)	0.20
	PD with familial background (n = 89)	35 (39.3 %)	42 (47.2 %)	12 (13.5 %)	0.71	112 (62.9 %)	66 (37.1 %)	0.49
	Healthy subjects (n = 241)	101 (41.9 %)	115 (47.7 %)	25 (10.4 %)		317 (65.8 %)	165 (34.2 %)	

		GG (UU)	GA (Uu)	AA (uu)		G (U)	A (u)	
rs757343 (Tru9I)	All PD (n = 381)	245 (64.3 %)	119 (31.2 %)	17 (4.5 %)	0.41	609 (79.9 %)	153 (20.1 %)	0.18
	PD sporadic (n = 292)	190 (65.1 %)	90 (30.8 %)	12 (4.1 %)	0.33	470 (80.5 %)	114 (19.5 %)	0.13
	PD sporadic age of onset >50 (n = 205)	136 (66.3 %)	60 (29.3 %)	9 (4.4 %)	0.31	332 (81.0 %)	78 (19.0 %)	0.12
	PD sporadic age of onset <50 (n = 87)	54 (62.1 %)	30 (34.5 %)	3 (3.4 %)	0.64	138 (79.3 %)	36 (20.7 %)	0.47
	PD with familial background (n = 89)	55 (61.8 %)	29 (32.6 %)	5 (5.6 %)	0.92	139 (78.1 %)	39 (21.9 %)	0.69
	Healthy subjects (n = 229)	136 (59.4 %)	79 (34.5 %)	14 (6.1 %)		351 (76.6 %)	107 (23.4 %)	>

		AA (BB)	AG (Bb)	GG (bb)		A (B)	G (b)	
rs1544410 (BsmI)	All PD (n = 380)	110 (28.9 %)	134 (35.3 %)	136 (35.8 %)	0.66	354 (46.6 %)	406 (53.4 %)	0.44
	PD sporadic (n = 292)	84 (28.8 %)	102 (34.9 %)	106 (36.3 %)	0.76	270 (46,2 %)	314 (53,8 %)	0.54
	PD sporadic age of onset >50 (n = 205)	60 (29.3 %)	70 (34.1 %)	75 (36.6 %)	0.84	190 (46.3 %)	220 (53.7 %)	0.55
	PD sporadic age of onset <50 (n = 87)	24 (27.6 %)	32 (36.8 %)	31 (35.6 %)	0.76	80 (46.0 %)	94 (54.0 %)	0.71
	PD with familial background (n = 88)	26 (29.5 %)	32 (36.4 %)	30 (34.1 %)	0.68	84 (47.7 %)	92 (52.3 %)	0.44
	Healthy subjects (n = 239)	67 (28.0 %)	78 (32.6 %)	94 (39.3 %)		212 (44.4 %)	266 (55.6 %)	>

		CC (FF)	CT (Ff)	TT (ff)		C (F)	T (f)	
rs2228570 (FokI)	All PD (n = 382)	181 (47.4 %)	164 (42.9 %)	37 (9.7 %)	0.75	526 (68.8 %)	238 (31.2 %)	0.47
	PD sporadic (n = 292)	133 (45.5 %)	133 (45.5 %)	26 (8.9 %)	0.81	399 (68.3 %)	185 (31.7 %)	0.62
	PD sporadic age of onset >50 (n = 205)	96 (46.8 %)	93 (45.4 %)	16 (7.8 %)	0.59	285 (69.5 %)	125 (30.5 %)	0.40
	PD sporadic age of onset <50 (n = 87)	37 (42.5 %)	40 (46.0 %)	10 (11.5 %)	0.98	114 (65.5 %)	60 (34.5 %)	0.75
	PD with familial background (n = 90)	48 (53.3 %)	31 (34.4 %)	11 (12.2 %)	0.22	127 (70.6 %)	53 (29.4 %)	0.37
	Healthy subjects (n = 237)	105 (44.3 %)	107 (45.1 %)	25 (10.5 %)		317 (66.9 %)	157 (33.1 %)	

* Compared with health subjects, Chi-square, *df*: 2 (for genotypes), *df*: 1 (for alleles), significance 2-sided; significance also confirmed with Cramer's V/Kendall's tau-c

Table 4 Comparisons of genotype distributions according to clinical features

	SNP ID	Genotypes	Initial symptom (frequency)		p	PD duration (frequency)		p	Disease stage (frequency)		p	FoG (frequency)		p	Falls (frequency)		p
			TD	AR or both		<7 years	≥7 years		<3	≥3		No	Yes		No	Yes	
ALL PD (independent from age of onset and familial background)	VDR-TaqI	TT	0.42	0.39	0.58	0.40	0.41	0.88	0.42	0.41	0.94	0.41	0.42	0.90	0.40	0.42	0.72
		Tt + tt	0.58	0.61		0.60	0.59		0.58	0.59		0.59	0.58		0.60	0.58	
	VDR-ApaI	AA	0.33	0.35	0.74	0.36	0.32	0.50	0.34	0.35	0.90	0.32	0.40	0.16	0.31	0.37	0.23
		Aa + aa	0.66	0.65		0.64	0.68		0.66	0.65		0.68	0.60		0.69	0.63	
	VDR-Tru9I	UU	0.65	0.63	0.62	0.65	0.62	0.48	0.64	0.63	0.89	0.65	0.60	0.36	0.66	0.62	0.48
		Uu + uu	0.35	0.37		0.35	0.38		0.36	0.37		0.35	0.40		0.34	0.38	
	VDR-BsmI	BB + Bb	0.63	0.66	0.14	0.64	0.65	0.93	0.62	0.66	0.45	0.62	0.68	0.31	0.63	0.65	0.67
		bb	0.37	0.34		0.36	0.35		0.38	0.35		0.38	0.32		0.37	0.35	
	VDR-FokI	FF	0.46	0.50	0.45	0.52	0.39	0.01 OR 1.7	0.51	0.41	0.07	0.48	0.43	0.38	0.48	0.45	0.65
		Ff + ff	0.54	0.50		0.48	0.61		0.49	0.59		0.52	0.58		0.52	0.55	
	GC-rs2282679	AA	0.58	0.55	0.53	0.53	0.65	0.03 OR 1.6	0.56	0.60	0.39	0.57	0.61	0.53	0.55	0.61	0.24
		CA + CC	0.42	0.45		0.47	0.35		0.44	0.40		0.43	0.39		0.45	0.39	
	GC-rs3755967	GG	0.57	0.55	0.64	0.53	0.64	0.03 OR 1.6	0.55	0.60	0.30	0.56	0.61	0.45	0.54	0.61	0.17
		GA + AA	0.43	0.45		0.47	0.36		0.45	0.40		0.44	0.39		0.46	0.39	
	GC-rs2298850	CC	0.57	0.56	0.74	0.53	0.64	0.04 OR 1.6	0.55	0.60	0.35	0.56	0.62	0.35	0.54	0.61	0.21
		CG + GG	0.43	0.44		0.47	0.36		0.45	0.40		0.44	0.38		0.46	0.39	
	GC-rs7041	GG	0.32	0.34	0.58	0.29	0.41	0.01 OR 1.7	0.28	0.38	0.05 OR 1.6	0.30	0.38	0.13	0.29	0.36	0.12
		GT + TT	0.68	0.66		0.71	0.59		0.72	0.62		0.70	0.62		0.71	0.64	
PD sporadic No familial background	VDR-TaqI	TT	0.42	0.37	0.39	0.41	0.38	0.58	0.43	0.40	0.73	0.42	0.40	0.72	0.41	0.42	0.91
		Tt + tt	0.58	0.63		0.59	0.62		0.57	0.60		0.58	0.60		0.59	0.58	
	VDR-ApaI	AA	0.31	0.34	0.56	0.32	0.33	0.93	0.32	0.33	0.83	0.30	0.38	0.17	0.29	0.35	0.25
		Aa + aa	0.69	0.66		0.68	0.67		0.68	0.67		0.70	0.62		0.71	0.65	
	VDR-Tru9I	UU	0.66	0.65	0.88	0.65	0.64	0.81	0.66	0.63	0.64	0.66	0.60	0.37	0.67	0.62	0.42
		Uu + uu	0.34	0.35		0.35	0.36		0.34	0.37		0.34	0.40		0.33	0.38	
	VDR-BsmI	BB + Bb	0.61	0.69	0.21	0.63	0.66	0.59	0.60	0.66	0.38	0.60	0.69	0.22	0.61	0.65	0.57
		bb	0.39	0.31		0.37	0.34		0.40	0.34		0.40	0.31		0.39	0.35	
	VDR-FokI	FF	0.43	0.51	0.18	0.50	0.38	0.05 OR 1.6	0.51	0.38	0.03 OR 1.7	0.47	0.40	0.29	0.48	0.43	0.42
		Ff + ff	0.57	0.49		0.50	0.62		0.49	0.62		0.53	0.60		0.52	0.57	
	GC-rs2282679	AA	0.60	0.53	0.26	0.55	0.63	0.16	0.55	0.61	0.28	0.56	0.63	0.28	0.53	0.62	0.14
		CA + CC	0.40	0.47		0.45	0.37		0.45	0.39		0.44	0.37		0.47	0.38	

Table 4 continued

SNP ID	Genotypes	Initial symptom (frequency)		p	PD duration (frequency)		p	Disease stage (frequency)		p	FoG (frequency)		p	Falls (frequency)		p
		TD	AR or both		<7 years	≥7 years		<3	≥3		No	Yes		No	Yes	
GC-rs3755967	GG	0.58	0.53	0.35	0.54	0.62	0.19	0.53	0.61	0.19	0.55	0.63	0.22	0.52	0.62	0.08
	GA + AA	0.42	0.47		0.46	0.38		0.47	0.39		0.45	0.37		0.48	0.38	
GC-rs2299850	CC	0.58	0.54	0.44	0.55	0.62	0.21	0.54	0.61	0.24	0.55	0.64	0.15	0.53	0.62	0.11
	CG + GG	0.42	0.46		0.45	0.38		0.46	0.39		0.45	0.36		0.47	0.38	
GC-rs7041	GG	0.33	0.36	0.54	0.31	0.41	0.08	0.29	0.39	0.09	0.31	0.40	0.16	0.30	0.37	0.19
	GT + TT	0.67	0.64		0.69	0.59		0.71	0.61		0.69	0.60		0.70	0.63	
PD sporadic Age onset >50																
VDR-TaqI	TT	0.45	0.37	0.25	0.41	0.43	0.79	0.41	0.45	0.65	0.41	0.49	0.36	0.41	0.45	0.59
	Tt + tt	0.55	0.63		0.59	0.57		0.59	0.55		0.59	0.51		0.59	0.55	
VDR-ApaI	AA	0.32	0.34	0.80	0.34	0.33	0.91	0.33	0.32	0.80	0.33	0.30	0.70	0.30	0.35	0.45
	Aa + aa	0.68	0.66		0.66	0.67		0.67	0.68		0.67	0.70		0.70	0.65	
VDR-Tru9I	UU	0.64	0.70	0.37	0.67	0.64	0.65	0.68	0.63	0.53	0.68	0.58	0.22	0.70	0.61	0.21
	Uu + uu	0.36	0.30		0.33	0.36		0.32	0.37		0.32	0.42		0.30	0.39	
VDR-BsmI	BB + Bb	0.59	0.72	0.06	0.64	0.64	0.99	0.61	0.65	0.65	0.62	0.65	0.69	0.61	0.65	0.62
	bb	0.41	0.28		0.36	0.36		0.39	0.35		0.38	0.35		0.39	0.35	
VDR-FokI	FF	0.41	0.56	0.04 OR 1.8	0.52	0.34	0.02 OR 2.1	0.50	0.40	0.17	0.45	0.47	0.87	0.49	0.42	0.39
	Ff + ff	0.59	0.44		0.48	0.66		0.50	0.60		0.55	0.53		0.51	0.58	
GC-rs2282679	AA	0.59	0.55	0.59	0.53	0.67	0.07	0.55	0.63	0.26	0.56	0.67	0.16	0.52	0.65	0.09
	CA + CC	0.41	0.45		0.47	0.33		0.45	0.37		0.44	0.33		0.48	0.35	
GC-rs3755967	GG	0.58	0.55	0.67	0.53	0.67	0.05 OR 1.8	0.54	0.63	0.21	0.55	0.67	0.14	0.52	0.65	0.06
	GA + AA	0.42	0.45		0.47	0.33		0.46	0.37		0.45	0.33		0.48	0.35	
GC-rs2299850	CC	0.58	0.55	0.67	0.53	0.66	0.11	0.55	0.62	0.34	0.55	0.67	0.14	0.52	0.64	0.12
	CG + GG	0.42	0.45		0.47	0.34		0.45	0.38		0.45	0.33		0.48	0.36	
GC-rs7041	GG	0.32	0.38	0.39	0.29	0.48	0.008 OR 2.3	0.27	0.43	0.02 OR 2.0	0.29	0.49	0.02 OR 2.3	0.27	0.41	0.04 OR 1.9
	GT + TT	0.68	0.62		0.71	0.52		0.73	0.57		0.71	0.51		0.73	0.59	
PD sporadic Age onset <50																
VDR-TaqI	TT	0.34	0.38	0.72	0.42	0.31	0.27	0.46	0.33	0.23	0.46	0.27	0.09	0.42	0.36	0.59
	Tt + tt	0.66	0.62		0.58	0.69		0.54	0.67		0.54	0.73		0.58	0.64	
VDR-ApaI	AA	0.28	0.35	0.46	0.29	0.33	0.65	0.26	0.35	0.38	0.19	0.50	0.004 OR 4.3	0.25	0.36	0.31
	Aa + aa	0.72	0.65		0.71	0.67		0.74	0.65		*0.81	0.50		0.75	0.64	
VDR-Tru9I	UU	0.70	0.54	0.13	0.60	0.64	0.68	0.60	0.63	0.80	0.60	0.63	0.79	0.58	0.64	0.59
	Uu + uu	0.30	0.46		0.40	0.36		0.40	0.37		0.40	0.37		0.42	0.36	
VDR-BsmI	BB + Bb	0.68	0.62	0.57	0.60	0.69	0.37	0.57	0.67	0.35	0.56	0.73	0.13	0.61	0.64	0.77
	bb	0.32	0.38		0.40	0.31		0.43	0.33		0.44	0.27		0.39	0.36	

Table 4 continued

SNP ID	Genotypes	Initial symptom (frequency)		p	PD duration (frequency)		p	Disease stage (frequency)		p	FoG (frequency)		p	Falls (frequency)		p
		TD	AR or both		<7 years	≥7 years		<3	≥3		No	Yes		No	Yes	
VDR-FokI	FF	0.47	0.41	0.57	0.42	0.43	0.95	0.54	0.35	0.08	0.52	0.30	0.05 OR 2.5	0.44	0.43	0.89
	Ff + ff	0.53	0.59		0.58	0.57		0.46	0.65		0.48	0.70*		0.56	0.57	
GC-rs2282679	AA	0.62	0.49	0.23	0.58	0.57	0.95	0.54	0.58	0.73	0.56	0.57	0.97	0.56	0.57	0.89
	CA + CC	0.38	0.51		0.42	0.43		0.46	0.42		0.44	0.43		0.44	0.43	
GC-rs3755967	GG	0.60	0.49	0.32	0.58	0.55	0.77	0.51	0.58	0.55	0.54	0.57	0.83	0.53	0.57	0.70
	GA + AA	0.40	0.51		0.42	0.45		0.49	0.42		0.46	0.43		0.47	0.43	
GC-rs2298850	CC	0.60	0.51	0.45	0.58	0.57	0.95	0.51	0.61	0.42	0.54	0.60	0.61	0.53	0.60	0.55
	CG + GG	0.40	0.49		0.42	0.43		0.49	0.39		0.46	0.40		0.47	0.40	
GC-rs7041	GG	0.34	0.32	0.88	0.38	0.31	0.50	0.34	0.30	0.70	0.35	0.27	0.42	0.36	0.29	0.48
	GT + TT	0.66	0.68		0.62	0.69		0.66	0.70		0.65	0.73		0.64	0.71	
PD with familial background																
VDR-TaqI	TT	0.39	0.44	0.68	0.35	0.50	0.18	0.40	0.46	0.60	0.38	0.50	0.35	0.39	0.45	0.60
	Tt + tt	0.61	0.56		0.65	0.50		0.60	0.54		0.62	0.50		0.61	0.55	
VDR-ApaI	AA	0.41	0.38	0.74	0.45	0.29	0.14	0.40	0.42	0.84	0.38	0.45	0.58	0.37	0.45	0.49
	Aa + aa	0.59	0.62		0.55	0.71		0.60	0.58		0.62	0.55		0.63	0.55	
VDR-Tru9I	UU	0.64	0.56	0.46	0.65	0.54	0.30	0.60	0.65	0.64	0.64	0.60	0.78	0.63	0.62	0.94
	Uu + uu	0.36	0.44		0.35	0.46		0.40	0.35		0.36	0.40		0.37	0.38	
VDR-BsmI	BB + Bb	0.70	0.58	0.28	0.70	0.61	0.41	0.65	0.65	0.96	0.66	0.65	0.93	0.66	0.65	0.96
	bb	0.30	0.42		0.30	0.39		0.35	0.35		0.34	0.35		0.34	0.35	
VDR-FokI	FF	0.56	0.47	0.40	0.60	0.41	0.09	0.51	0.56	0.69	0.51	0.52	0.90	0.48	0.57	0.45
	Ff + ff	0.44	0.53		0.40	0.59		0.49	0.44		0.49	0.48		0.52	0.43	
GC-rs2282679	AA	0.54	0.63	0.46	0.50	0.72	0.04 OR 2.6	0.58	0.56	0.82	0.60	0.52	0.52	0.59	0.57	0.82
	CA + CC	0.46	0.37		0.50	0.28		0.42	0.44		0.40	0.48		0.41	0.43	
GC-rs3755967	GG	0.54	0.63	0.46	0.50	0.72	0.04 OR 2.6	0.58	0.56	0.82	0.60	0.52	0.52	0.59	0.57	0.82
	GA + AA	0.46	0.37		0.50	0.28		0.42	0.44		0.40	0.48		0.41	0.43	
GC-rs2298850	CC	0.54	0.63	0.46	0.50	0.72	0.04 OR 2.6	0.58	0.56	0.82	0.60	0.52	0.52	0.59	0.57	0.82
	CG + GG	0.46	0.37		0.50	0.28		0.42	0.44		0.40	0.48		0.41	0.43	
GC-rs7041	GG	0.28	0.28	0.99	0.22	0.41	0.05 OR 2.5	0.26	0.33	0.45	0.27	0.33	0.58	0.26	0.33	0.47
	GT + TT	0.72	0.72		0.78	0.59		0.74	0.67		0.73	0.67		0.74	0.67	

Chi-square; *df*: 1; significance 2-sided; significance also confirmed with Cramer's V/Kendall's tau-c